Araclon Biotech, S.L.

At Araclon Biotech, a Grifols company, we focus on the early diagnosis and preventive treatment of Alzheimer’s disease. We are pioneers in plasma-based assays for detecting amyloid peptides and have developed ABvac40, an innovative vaccine targeting Aβ40 to slow disease progression. Since our founding in 2004 by Prof. Manuel Sarasa Barrio as a spin-off from the University of Zaragoza, we have grown into a leader in Alzheimer’s research, committed to scientific excellence and innovation. As part of Grifols, we continue to develop groundbreaking solutions that improve the lives of individuals affected by neurodegenerative diseases.